Evercore (EVR) Company Report

Atea Pharmaceuticals reported cash, cash equivalents and marketable securities of $329.3 million as of September 30, 2025, compared to $454.7 million at December 31, 2024. For the three months ended September 30, 2025, the company recorded a net loss of $42.049 million and a net loss per share of $0.53.
The global Phase 3 program for the bemnifosbuvir/ruzasvir regimen for Hepatitis C Virus (HCV) is progressing, with topline results for the C-BEYOND trial in North America expected in mid-2026 and for the C-FORWARD trial (outside North America) around the end of 2026.
The company expanded its antiviral pipeline with a new Hepatitis E Virus (HEV) development program, anticipating Phase 1 studies for its lead candidates, AT-587 and AT-2490, to begin in mid-2026.
Atea completed its share repurchase program, buying back 7,673,793 shares at an average price of $3.26 per share, resulting in 78,126,796 shares outstanding.

Nov 12, 2025, 9:05 PM

Press Release

Precision Concepts International Acquires Comar

EVR

M&A

New Projects/Investments

Precision Concepts International (PCI), a portfolio company of The Sterling Group, has acquired Comar.
This acquisition establishes a scaled rigid packaging platform serving diverse consumer and healthcare customers across North America.
The combination is expected to enhance PCI's capabilities, broaden its product and service offerings, and provide enhanced geographic, customer, and end market diversification.
Evercore acted as the financial advisor to PCI for this transaction.

Nov 4, 2025, 2:00 PM

Press Release

State Street Investment Management Makes Strategic Investment in Coller Capital

EVR

M&A

New Projects/Investments

State Street Investment Management has made a strategic minority investment in Coller Capital, a private market secondaries manager, with the aim of broadening both firms’ reach and unlocking new opportunities in the rapidly growing private capital secondaries market.
State Street Investment Management, which manages over $5 trillion in assets, will benefit from access to Coller’s extensive capabilities in private equity and private credit secondaries.
Coller Capital, managing over $46 billion in secondaries assets, will use the investment and strategic relationship to support its long-term growth strategy and expand access to secondaries to a broader range of investors and markets.
The secondaries market transacted over $160 billion in 2024, with projections for this volume to expand to nearly $500 billion by 2030.

Nov 3, 2025, 1:30 PM

Press Release

Evercore Reports Strong Q3 2025 Financial Results

EVR

Earnings

Revenue Acceleration/Inflection

Evercore reported Q3 2025 revenue of approximately $1.04 to $1.05 billion, representing a year-over-year increase of around 41%.
The company's adjusted earnings per share for Q3 2025 was $3.48, surpassing analyst expectations by over 15%.
Evercore achieved an impressive Return on Equity (ROE) of 29.1% and maintained a solid balance sheet with $851.9 million in cash and cash equivalents and over $1.6 billion in investment securities.
The firm's annualized revenue growth accelerated to 19.4% over the last two years, exceeding its five-year compound annual growth rate of 11.9%.

Oct 29, 2025, 1:52 PM

Morningstar

Evercore Reports Record Third Quarter 2025 Results

EVR

Earnings

Hiring

Revenue Acceleration/Inflection

Evercore delivered record third quarter 2025 results, with adjusted net revenues of $1 billion, marking a 42% increase year-over-year, and adjusted earnings per share (EPS) of $3.48, up 71% from the prior year.
The company experienced broad-based strength across its diversified platform, with adjusted advisory fees increasing 49% year-over-year to $884 million, and commissions and related revenue growing 15% year-over-year to $63 million.
Record Senior Managing Director (SMD) recruiting in 2025 has increased the total to 168 investment banking SMDs, positioning the firm well as the market strengthens.
Wealth management achieved a record quarter-end AUM of approximately $15.4 billion, driven by market appreciation and strong net client inflows.
The company repurchased approximately 170,000 shares at an average price of $326.62 in Q3 2025, contributing to a total of $624 million returned to shareholders through repurchases and dividends through the end of Q3.

Oct 29, 2025, 12:00 PM

Transcript

Evercore Reports Record Q3 2025 Financial Results

EVR

Earnings

Revenue Acceleration/Inflection

Hiring

Evercore delivered record third quarter 2025 adjusted net revenues of $1 billion, marking a 42% increase year over year, and adjusted earnings per share of $3.48, up 71% compared to the prior year period.
The company experienced broad-based strength across its diversified platform, with adjusted advisory fees growing 49% year over year to $884 million (a Q3 record) and commissions and related revenue increasing 15% to $63 million (a record Q3 and highest in nearly a decade).
Evercore continued its strategic talent expansion, closing the Robey Warshaw transaction and reaching 168 investment banking Senior Managing Directors, up nearly 50% from year-end 2021, making 2025 its strongest recruiting year to date.
The company repurchased approximately 170,000 shares at an average price of $326.62 during Q3 2025, contributing to $624 million in capital returned to shareholders through the end of Q3.
Management expects continued strengthening in the market and business, with backlogs increasing, and anticipates the full-year compensation ratio to be generally in line with Q3's 65%, while striving for gradual improvement over time.

Oct 29, 2025, 12:00 PM

Transcript

Evercore Inc. Announces Record Q3 2025 Results, Robey Warshaw Acquisition, and Capital Returns

EVR

Earnings

M&A

Share Buyback

Evercore Inc. reported record Third Quarter Net Revenues of $1.0 billion on a U.S. GAAP basis and $1.05 billion on an Adjusted basis for Q3 2025, marking increases of 41% and 42% respectively, compared to Q3 2024.
Diluted Earnings Per Share for Q3 2025 rose to $3.41 (U.S. GAAP) and $3.48 (Adjusted), up from $1.86 and $2.04 in Q3 2024, respectively.
The acquisition of Robey Warshaw closed on October 1, 2025, adding five Investment Banking Senior Managing Directors to Evercore.
The company declared a quarterly dividend of $0.84 per share and returned $623.8 million to shareholders during the first nine months of 2025 through dividends and repurchases of 1.9 million shares.

Oct 29, 2025, 10:45 AM

8-K

BioCryst to Acquire Astria Therapeutics

EVR

M&A

New Projects/Investments

Guidance Update

BioCryst Pharmaceuticals has entered into a definitive agreement to acquire Astria Therapeutics for an implied value of approximately $920 million in aggregate equity-value and $700 million in enterprise value.
Astria stockholders will receive $8.55 in cash and 0.59 shares of BioCryst common stock per share, with the transaction expected to close in the first quarter of 2026.
The acquisition will add navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development for hereditary angioedema (HAE) prophylaxis, to BioCryst's portfolio.
BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction, with the deal anticipated to be accretive to operating profit (non-GAAP) in the first full year of revenue after navenibart's launch.
Astria stockholders are projected to own approximately 15% of proforma equity in the combined company.

Oct 14, 2025, 11:00 AM

Press Release

BioCryst to Acquire Astria Therapeutics

EVR

M&A

New Projects/Investments

Revenue Acceleration/Inflection

BioCryst Pharmaceuticals, Inc. will acquire Astria Therapeutics, Inc. for an implied value of $13.00 per Astria share, totaling an implied enterprise value of approximately $700 million. The consideration per share includes $8.55 in cash and 0.59 shares of BioCryst common stock.
The acquisition will add navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development for hereditary angioedema (HAE) prophylaxis, to BioCryst's portfolio.
BioCryst expects the transaction to solidify a double-digit growth trajectory for its HAE portfolio over the next decade and anticipates remaining profitable (non-GAAP) and cash flow positive post-transaction.
The transaction is expected to close in the first quarter of 2026, pending customary approvals.

Oct 14, 2025, 11:00 AM

Press Release

Zenas BioPharma Announces License Agreement and Private Placement Financing

EVR

New Projects/Investments

Zenas BioPharma has entered into a transformational license agreement with InnoCare Pharma, securing global development and commercialization rights to orelabrutinib for Multiple Sclerosis (MS) and non-oncology areas, along with rights to two other novel oral inhibitors.
The agreement includes upfront and near-term milestone payments of up to $100 million in cash and up to 7,000,000 shares of Zenas common stock, with total potential payments exceeding $2 billion and tiered royalties up to high teens percentages on annual net sales.
Orelabrutinib is currently in Phase 3 development for Primary Progressive MS (PPMS), with a Phase 3 trial for Secondary Progressive MS (SPMS) expected to initiate in Q1 2026. The other two licensed inhibitors are expected to begin Phase 1 clinical trials in 2026.
Zenas also announced a $120.0 million private placement financing, which is projected to extend its cash, cash equivalents, and investments into Q4 2026, or into Q1 2027 if a potential $75 million milestone from Royalty Pharma is received.

Oct 8, 2025, 9:00 AM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Evercore.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did John Weinberg say about margins?What are Evercore's strategic priorities?How is Evercore positioned vs competitors?How did Evercore do last quarter?

Let Fintool AI Agent track Evercore's earnings for you

Get instant analysis when filings drop